Scientific Consultant, MedLearning, Inc. Hasbrouck Heights, NJ, USA.
SUNY Upstate Medical University, Syracuse, NY, USA.
J Atten Disord. 2023 Jan;27(1):14-25. doi: 10.1177/10870547221112948. Epub 2022 Jul 29.
Few studies of prescription stimulant non-oral, non-medical use (NMU) (defined by use not as prescribed) have been conducted in adults beyond the college population. The purpose of this study was to characterize prescription stimulant non-oral use, specifically intranasal (IN) use (snorting) in young adults.
Amazon's MTurk platform was used to recruit participants for an online survey. Data were collected from March to April 2020.
Thirty-two percent ( = 157) of survey respondents ( = 975), aged 18 to 30, reported IN prescription stimulant use (average of 32.1 episodes of lifetime IN use). Adderall was the most-reported prescription stimulant used intranasally (89.2%). Most IN users (82%; = 68) reported spending no more than 5 minutes tampering with prescription stimulants. Intranasal users said they would take the medication orally if unable to tamper or manipulate medication for IN use.
These data help quantify a complex public health issue of ongoing IN use of prescription stimulants and suggest a potential role for manipulation-deterrent medications.
在大学生群体之外，针对成年人的处方兴奋剂非口服、非医疗用途（定义为未按规定使用）研究甚少。本研究旨在描述处方兴奋剂的非口服使用情况，特别是年轻人的鼻腔内（鼻内）使用（吸食）。
亚马逊的 MTurk 平台被用于招募参与在线调查的参与者。数据收集于 2020 年 3 月至 4 月期间。
在 18 至 30 岁的 975 名调查受访者中，有 32%（=157 人）报告了鼻腔内使用处方兴奋剂（一生中有 32.1 次鼻腔内使用的平均记录）。安非他命是最常被报告用于鼻腔内使用的处方兴奋剂（89.2%）。大多数鼻内使用者（82%；=68）表示他们用于篡改药物的时间不超过 5 分钟。如果无法篡改或操纵药物用于鼻内使用，鼻内使用者表示他们将口服药物。
这些数据有助于量化持续存在的处方兴奋剂鼻内使用这一复杂的公共卫生问题，并表明有必要使用防篡改药物。
